Summary

Wilms' Tumor (Nephroblastoma) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Wilms' Tumor (Nephroblastoma) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Wilms' Tumor (Nephroblastoma), complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

The report is built using data and information sourced from Global Ma...

Summary

Benign Tumor Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Benign Tumor pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Benign Tumor, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university website...

Summary

Tenosynovial Giant Cell Tumor Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Tenosynovial Giant Cell Tumor pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Tenosynovial Giant Cell Tumor, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

The report is built using data and information sourced from Global Markets Direct’...

Summary

Primitive Neuroectodermal Tumor (PNET) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Primitive Neuroectodermal Tumor (PNET) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Primitive Neuroectodermal Tumor (PNET), complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

The report is built using data and information sourced fr...

Summary

Biliary Tumor Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Biliary Tumor pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Biliary Tumor, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university webs...

Summary

Tumor Necrosis Factor Ligand Superfamily Member 4 (Glycoprotein Gp34 or OX40 Ligand or TAX Transcriptionally Activated Glycoprotein 1 or CD252 or TNFSF4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players report provides in depth analysis on Tumor Necrosis Factor Ligand Superfamily Member 4 (Glycoprotein Gp34 or OX40 Ligand or TAX Transcriptionally Activated Glycoprotein 1 or CD252 or TNFSF4) targeted pipeline therapeutics. The report provides comprehensive information complete with Analysis by Indications, Stage of Development, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Additionally, the report analyses the pipeline products across relevant therapy areas under development and provides an overview of key players involved in Tumor Necrosis Factor Ligand Superfamily Member 4 (Glycoprotein Gp34 or OX40 Ligand ...

Summary

Papillary Tumor Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Papillary Tumor pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Papillary Tumor, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/universit...

Summary

Pituitary Tumor Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Pituitary Tumor pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Pituitary Tumor, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/universit...

Summary

Brain Tumor Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Brain Tumor pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Brain Tumor, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, ...

Summary

GlobalData's clinical trial report, “Brain Tumor Global Clinical Trials Review, H1, 2020" provides an overview of Brain Tumor Clinical trials scenario. This report provides top line data relating to the clinical trials on Brain Tumor. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage....

Summary

Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Tumor Necrosis Factor Receptor Superfamily Member 4 or OX40 is a member of the TNF-receptor superfamily. This receptor has been shown to activate NF-kappaB through its interaction with adaptor proteins TRAF2 and TRAF5. OX40L binds to OX40 receptors on T-cells, preventing them from dying and subsequently increasing cytokine production. OX40 has a critical role in the maintenance of an immune response. OX40 also plays a crucial role in both Th1 and Th2 mediated reactions.

Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) pipeline Target constitutes close to 26 molecules. Out of which approximately 25 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discov...

Summary

Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) pipeline Target constitutes close to 25 molecules. Out of which approximately 23 molecules are developed by companies and remaining by the universities/institutes. The latest report Tumor Necrosis Factor Receptor Superfamily Member 5 - Pipeline Review, H1 2019, outlays comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Tumor Necrosis Factor Receptor Superfamily Member 5 is a member of the TNF-receptor superfamily. This protein is a receptor on antigen-presenting cells of the immune system and is essential for m...

Summary

GlobalData's clinical trial report, “Wilms' Tumor (Nephroblastoma) Global Clinical Trials Review, H2, 2018" provides an overview of Wilms' Tumor (Nephroblastoma) clinical trials scenario. This report provides top line data relating to the clinical trials on Wilms' Tumor (Nephroblastoma). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to c...

Summary

GlobalData's clinical trial report, “Tumor Lysis Syndrome Global Clinical Trials Review, H2, 2018" provides an overview of Tumor Lysis Syndrome clinical trials scenario. This report provides top line data relating to the clinical trials on Tumor Lysis Syndrome. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to g...

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline Review, H1 2018, provides an overview of the Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology) pipeline landscape.

Malignant peripheral nerve sheath tumors (MPNSTs) are sarcomas which originate from peripheral nerves or from cells associated with the nerve sheath, such as Schwann cells, perineural cells, or fibroblasts. Symptoms include lump or swelling in the in the soft tissue, numbness, burning or having that pins and needles feeling, weakness in the affected muscles and dizziness or loss of balance. Treatment includes surgery, radiotherapy and chemotherapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology), complete ...

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ependymoma - Pipeline Review, H1 2018, provides an overview of the Ependymoma (Oncology) pipeline landscape.

Ependymoma is a type of glioma that develops from ependymal cells. Ependymomas usually develop in the lining of the ventricles or in the spinal cord. The most common place they are found in children is near the cerebellum. The tumor often blocks the flow of the cerebral spinal fluid (CSF), causing increased intracranial pressure. Ependymomas are often slow growing tumors, and any signs and symptoms usually develop slowly over many months. The treatment for an ependymoma depends on a number of things, including general health, the size and position of the tumor, and whether it has spread to other parts of the brain or spinal cord.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ependymoma - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Ep...

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline Review, H2 2017, provides an overview of the Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology) pipeline landscape.

Malignant peripheral nerve sheath tumors (MPNSTs) are sarcomas which originate from peripheral nerves or from cells associated with the nerve sheath, such as Schwann cells, perineural cells, or fibroblasts. Symptoms include lump or swelling in the in the soft tissue, numbness, burning or having that pins and needles feeling, weakness in the affected muscles and dizziness or loss of balance. Treatment includes surgery, radiotherapy and chemotherapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology), complete...

Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Wilms' Tumor (Nephroblastoma) Overview 6
Therapeutics Development 7
Pipeline Products for Wilms' Tumor (Nephroblastoma) - Overview 7
Pipeline Products for Wilms' Tumor (Nephroblastoma) - Comparative Analysis 8
Wilms' Tumor (Nephroblastoma) - Therapeutics under Development by Companies 9
Wilms' Tumor (Nephroblastoma) - Therapeutics under Investigation by Universities/Institutes 10
Wilms' Tumor (Nephroblastoma) - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Wilms' Tumor (Nephroblastoma) - Products under Development by Companies 13
Wilms' Tumor (Nephroblastoma) - Products under Investigation by Universities/Institutes 14
Wilms' Tumor (Nephroblastoma) - Companies Involved in Therapeutics Development 15
Exelixis Inc 15
NanoSmart Pharmaceuticals Inc 16
Recombio SL 17
Selvita SA 18
Wilms' Tumor (Nephroblasto...

Summary

Global Markets Direct’s, ‘Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) - Pipeline Review, H2 2016’, provides in depth analysis on Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) targeted pipeline therapeutics.

The report provides comprehensive information on the Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s repor...

Summary

Global Markets Direct’s, ‘Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS)  - Pipeline Review, H2 2016’, provides in depth analysis on Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS)  targeted pipeline therapeutics.

The report provides comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Tumor Necrosis...

Summary

Global Markets Direct’s, ‘Tumor Necrosis Factor Ligand Superfamily Member 13B (B Lymphocyte Stimulator or Dendritic Cell Derived TNF Like Molecule or TNF And APOL Related Leukocyte Expressed Ligand 1 or CD257 or TNFSF13B) - Pipeline Review, H2 2016’, provides in depth analysis on Tumor Necrosis Factor Ligand Superfamily Member 13B (B Lymphocyte Stimulator or Dendritic Cell Derived TNF Like Molecule or TNF And APOL Related Leukocyte Expressed Ligand 1 or CD257 or TNFSF13B) targeted pipeline therapeutics.

The report provides comprehensive information on the Tumor Necrosis Factor Ligand Superfamily Member 13B (B Lymphocyte Stimulator or Dendritic Cell Derived TNF Like Molecule or TNF And APOL Related Leukocyte Expressed Ligand 1 or CD257 or TNFSF13B), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest ne...